Strategic partnerships Evidenze has recent collaboration announcements with Telefonica and Columna Capital, signaling openness to strategic alliances and investment to accelerate growth in Europe and in clinical data initiatives. Leverage partner ecosystems to cross-sell CRO value and data space offerings to telecom and investment networks.

Data space expansion The launch of Nefro Data Space developed with reputable institutions indicates a focus on specialized data platforms for nephrology. This creates a sales opportunity to offer data management, analytics, and regulatory consulting services around niche therapeutic areas.

Full Value CRO positioning Evidenze markets itself as a Full Value CRO that combines technology, strategic consultancy, and regulatory approach beyond traditional CRO services. This differentiation can be used to upsell integrated trials optimization, cost reduction, and early regulatory strategy during client engagement.

Global reach with tech stack With a global-reach approach and an tech-enabled stack (cloud, analytics, collaboration tools), Evidenze can target mid-market biotechs and regional pharma companies seeking scalable, tech-driven clinical trial execution and faster time-to-market.

Mid-market growth signals Revenue in the $1M–$10M range and 51–200 employees place Evidenze in the mid-market segment, suggesting opportunities to scale through tiered service offerings, add-on data services, and modular regulatory consulting as clients expand trials and launches.